Walleye Capital
MDGL icon

Walleye Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Walleye Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-700
Closed -$408K – 4729
2025
Q4 		$408K Sell
700
-200
-22% -$102K ﹤0.01% 3084
2025
Q3 		$413K Buy
900
+500
+125% +$187K ﹤0.01% 2775
2025
Q2 		$121K Sell
400
-300
-43% -$89.4K ﹤0.01% 3676
2025
Q1 		$232K Sell
700
-400
-36% -$131K ﹤0.01% 3157
2024
Q4 		$339K Buy
+1,100
New +$309K ﹤0.01% 3322
2024
Q3 		– Sell
-900
Closed -$252K – 5645
2024
Q2 		$252K Buy
900
+400
+80% +$95.2K ﹤0.01% 4124
2024
Q1 		$134K Buy
+500
New +$118K ﹤0.01% 4220
2023
Q2 		– Sell
-400
Closed -$96.9K – 4651
2023
Q1 		$96.9K Buy
+400
New +$109K ﹤0.01% 2947
2020
Q1 		– Sell
-1,600
Closed -$146K – 1370
2019
Q4 		$146K Sell
1,600
-3,000
-65% -$291K 0.01% 1250
2019
Q3 		$397K Sell
4,600
-14,600
-76% -$1.37M 0.02% 859
2019
Q2 		$2.01M Buy
19,200
+18,500
+2,643% +$1.98M 0.22% 90
2019
Q1 		$88K Buy
+700
New +$87K 0.01% 1078

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's MDGL Position: Q1 2026 in Review

Walleye Capital increased its Madrigal Pharmaceuticals (MDGL) stake by 19,070% in Q1 2026, buying an estimated $6.29M and bringing the position to 13,227 shares worth $6.92M. The position accounts for 0.03% of the portfolio, ranked #597.

Walleye Capital first reported a position in MDGL in Q4 2019 and has held it in 6 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Walleye Capital held 13,227 shares of Madrigal Pharmaceuticals worth $6.92M as of Q1 2026.
  • Walleye Capital bought 13,158 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $6.29M.
  • Madrigal Pharmaceuticals made up 0.03% of Walleye Capital's portfolio in Q1 2026, its #597 holding.
  • Walleye Capital first reported a position in Madrigal Pharmaceuticals in Q4 2019 and has held it in 6 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.